The problem of adrenocortical cancer therapy


Cite item

Full Text

Abstract

Adrenocortical carcinoma (ACC) - a rare and very aggressive malignant tumor originating from the adrenal cortex. About 60% of tumors are hormone producing. Surgical treatment is the only method that can heal the sick ACC. Adjuvant therapy may be recommended for patients with a high risk of relapse. Treatment of advanced ACC includes systemic therapy in combination with local methods of exposure, such as surgery, radiofrequency ablation, and chemoembolization. For the treatment of ACC uses a combination of steroidogenesis mitotane inhibitor with cytotoxic drugs. The most effective chemotherapy regimen in metastatic ACC is a combination of etoposide, doxorubicin and cisplatin against the background of continuous use mitotane (Scheme EPD-M). In the second-line treatment is possible to use a combination of gemcitabine and fluoropyrimidines. The results from the use ACC drugs, which have direct action on the receptor of insulin-like growth factor (IGF-1R) and insulin receptor (IR) as a monotherapy and in combination with inhibitors ofserine-threonine kinase mTOR. The clinical introduction of new effective drugs will improve the results of patients with ACC treatment.

About the authors

Alina A. Kolomeytseva

N.N. Blokhin Russian Cancer Research Center

Email: almed2002@mail.ru
MD, Phd 115478, Moscow, Russian Federation

V. A Gorbunova

N.N. Blokhin Russian Cancer Research Center

115478, Moscow, Russian Federation

N. I Perevodchikova

N.N. Blokhin Russian Cancer Research Center

115478, Moscow, Russian Federation

References

  1. Dackiw A.P., Lee J.E., Gagel R.F., Evans D.B. Adrenal cortical carcinoma. World J. Surg. 2001; 25: 914-26.
  2. Wajchenberg B.L., Albergaria Pereira M.A., Medonca B.B., Latronico A.C., Campos C.P., Alves V.A. et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer. 2000; 88: 711-36.
  3. Fassnacht M., Libe R., Kroiss M., Allolio B. Adrenocortical carcinoma:a clinician’s update. Nat. Rev. Endocrinol. 2011; 7: 323-35.
  4. Kirschner L.S. Emerging treatment strategies for adrenocortical carcinoma: a new hope. J. Clin. Endocrinol. Metab. 2006; 91: 14-21.
  5. Gicquel C., Bertagna X., Schneid H., Francillard-Leblond M., Luton J.P., Girard F., Le Bouc Y. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 1994; 78: 1444-53.
  6. Barlaskar F.M., Spalding A.C., Heaton J.H., Kuick R., Kim A.C., Thomas D.G. et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2009; 94: 204-12.
  7. Tissier F., Cavard C., Groussin L., Perlemoine K., Fumey G., Hagnere A.M. et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005; 65: 7622-7.
  8. Bonnet S., Gaujoux S., Launay P., Baudry C., Chokri I., Ragazzon B. et al. Wnt/beta-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and nonsecreting tumors. J. Clin. Endocrinol. Metab. 2011; 96: E419-26.
  9. Lalli E. Adrenocortical development and cancer: focus on SF-1. J. Mol. Endocrinol. 2010; 44: 301-7.
  10. Duregon E., Volante M., Giorcelli J., Terzolo M., Lalli E., Papotti M. Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. Hum. Pathol. 2013; 44: 822-8.
  11. Herrmann L.J., Heinze B., Fassnacht M., Willenberg H.S., Quinkler M., Reisch N. et al. TP53 germline mutations in adult patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2012; 97: E476-85.
  12. Raymond V.M., Else T., Everett J.N., Long J.M., Gruber S.B., Hammer G.D. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2013; 98: E119-25.
  13. De Reynies A., Assi G., Rickman D.S., Tissier F., Groussin L., Rene-Corail F. et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 2009; 27(7): 1108-15.
  14. DeLellis R.A., Lloyd R.V., Heitz P.U., Eng C. World Health Organization Classification of Tumours, Pathology, and Genentics of Tumours of Endocrine Organs. Lyon: IARC Press; 2004.
  15. Komminoth P., Roth J., Schroder S., Saremaslani P., Heitz P. Overlapping expression of immunohistochemical markers and synaptophysin mRNA in pheochromocytomas and adrenocortical carcinomas. Implications for the differential diagnosis of adrenal gland tumors. Lab. Invest. 1995; 72: 424-31.
  16. Enriquez M.L., Lal P., Ziober A., Wang L., Tomaszewski J.E., Bing Z. The use of immunohistochemical expression of SF-1 and EMA in distinguishing adrenocortical tumors from renal neoplasms. Appl. Immunohistochem. Mol. Morphol. 2012; 20: 141-5.
  17. Nakazumi H., Sasano H., Iino K., Ohashi Y., Orikasa S. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. Mod. Pathol. 1998; 11: 1165-70.
  18. Aubert S., Wacrenier A., Leroy X., Devos P., Carnaille B., Proye C. et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am. J. Surg. Pathol. 2002; 26(12): 1612-9.
  19. Welch T.J., Sheedy P.F. II, Stephens D.H., Johnson C.M., Swensen S.J. Percutaneous adrenal biopsy: review of a 10-year experience. Radiology. 1994; 193: 341-4.
  20. Glover A.R., Ip J.C.Y. et al. Current management options for recurrent adrenocortical carcinoma. Onco Targets Ther. 2013; 6: 635-43.
  21. Terzolo M., Angeli A., Fassnacht M., Daffara F., Tauchmanova L., Conton P.A. et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med. 2007; 356: 2372-80.
  22. Fassnacht M., Hahner S., Polat B., Koschker A.C., Kenn W., Flentje M., Allolio B. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2006; 91: 4501-4.
  23. Sabolch A., Feng M., Griffith K., Hammer G., Doherty G., Ben-Josef E. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2011; 80: 1477-84.
  24. Habra M.A., Ejaz S., Feng L., Das P., Deniz F., Grubbs E.G. et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab.2013; 98: 192-7.
  25. Khan T.S., Imam H., Juhlin C., Skogseid B., Grondal S., Tibblin S. et al. Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann. Oncol.: Offic. J. Eur. Soc. Med. Oncol. 2000; 11: 1281-7.
  26. Malandrino P., Al Ghuzlan A., Castaing M., Young J., Caillou B., Travagli J.-P. et al. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr. Relat. Cancer. 2010; 17(3): 797-807.
  27. Assie'G., Antoni G., Tissier F., Caillou B., Abiven G., Gicquel C. et al. Prognostic parameters of metastatic adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2007; 92(1): 148-54.
  28. Abiven G., Coste J., Groussin L. et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J. Clin. Endocrinol. Metab. 2006; 91(7): 2650-5.
  29. Bellantone R., Ferrante A., Boscherini M., Lombardi C.P., Crucitti P., Crucitti F. et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for adrenal cortical carcinoma. Surgery. 1997; 122: 1212-8.
  30. Wood B.J., Abraham J., Hvizda J.L., Alexander H.R., Fojo T. et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer. 2003; 97(3): 554-60.
  31. Cazejust J., De Bae're T., Auperin A., Deschamps F., Hechelhammer L., Abdel-Rehim M. et al. Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J. Vasc. Interv. Radiol. 2010; 21: 1527-32.
  32. Hahner S., Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr. Opin. Invest. Drugs. 2005; 6: 386-94.
  33. Fassnacht M., Terzolo M., Allolio B., FIRM-ACT Study Group et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 2012; 366(23): 2189-97.
  34. Sperone P., Ferrero A., Daffara F., Priola A., Zaggia B., Volante M. et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr. Relat. Cancer. 2010; 17(2): 445-53.
  35. Carden C.P., Kim E.S., Jones R.L. et al. Phase I study of intermittent dosing of OSI-906, a dual tirosine kinase inhibitor of insulinlike growth factor 1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors. J. Clin. Oncol. 2010; 28 (Suppl. 15): Abstr. 2530.
  36. A study of OSI-906 in patients with locally advanced or metastatic adrenocortical carcinoma (GALACCTIC). In: Clinical Trials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2009 [updated 2012]. Available from http://clinicaltrials.gov/show/NCT00924989. NLM identifier NCT00924989. Accessed January 10, 2013.
  37. Fraenkel M., Gueorguiev M., Barak D., Salmon A., Grossman A.B., Gross D.J. Everolimus therapy for progressive adrenocortical cancer. Endocrine. 2013; 44: 187-92.
  38. Naing A., Lorusso P., Fu S., Hong D.S., Anderson P., Benjamin R.S. et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br. J. Cancer. 2013; 108: 826-30.

Copyright (c) 2014 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies